Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mouse CD3 complex (CD3) is a vital multi-subunit transmembrane protein assembly found on the surface of T lymphocytes, consisting of four distinct polypeptide chains: CD3 epsilon (Cd3e), CD3 delta (Cd3d), CD3 gamma (Cd3g), and CD3 zeta (Cd247) (UniProt: P04235, P04234). It serves as the primary signaling component of the T-cell receptor (TCR) complex, where it facilitates the transduction of signals from the extracellular environment into the cytoplasm following antigen recognition (PubMed: 15365095). This signaling is mediated by immunoreceptor tyrosine-based activation motifs (ITAMs) located within the cytoplasmic tails of the CD3 subunits, which, upon phosphorylation, trigger downstream pathways essential for T-cell activation, proliferation, and differentiation (NCBI Gene: 12501). In preclinical research, the murine CD3 complex is a major therapeutic target for immunomodulatory agents, including monoclonal antibodies like 145-2C11 and 17A2, which are used to study T-cell depletion and the induction of immune tolerance in models of autoimmune diseases and organ transplantation (PubMed: 21441452). Furthermore, it is frequently utilized in the development of bispecific T-cell engagers (BiTEs) within syngeneic mouse tumor models to evaluate the efficacy of redirecting T cells against cancer cells. Despite its therapeutic utility, targeting the CD3 complex is associated with significant safety concerns, such as cytokine release syndrome (CRS) and systemic inflammation, resulting from the massive release of pro-inflammatory cytokines like TNF-alpha and IFN-gamma (PubMed: 10741414).
The mechanism of action involves the binding of monoclonal antibodies to the CD3 epsilon subunit, which can either trigger agonistic T-cell receptor signaling leading to activation or induce T-cell depletion through Fc-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (PubMed: 21441452).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mouse CD3 complex (CD3) (CD3).